Linagliptin

# Linagliptin ## Overview - **Classification**: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor - **Mechanism**: Inhibits DPP-4 enzyme, preventing breakdown of incretin hormones (GLP-1, GIP). This increases insulin synthesis/release from beta cells and decreases glucagon secretion in a glucose-dependent manner. ## Primary Indications 1. **Type 2 Diabetes Mellitus (T2DM)** - As an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: **5 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: Chronic ### Dose Adjustments - **Renal Impairment**: No dose adjustment required. - **Hepatic Impairment**: No dose adjustment required. - **Elderly Patients**: No dose adjustment required. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not FDA approved for pediatric use. - **Special Notes**: Safety and efficacy not established. ### Infants (1-12 months) - **Dose**: Not FDA approved for pediatric use. ### Children (1-12 years) - **Dose**: Not FDA approved for pediatric use. ### Adolescents (13-18 years) - **Dose**: Not FDA approved for pediatric use. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to linagliptin or any excipient. - **Absolute**: History of serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to linagliptin. ### Common Adverse Effects - **Common (1-10%)**: Nasopharyngitis, cough, diarrhea, back pain. - **Serious but Rare**: Pancreatitis, bullous pemphigoid, severe arthralgia, hypersensitivity reactions. ### Key Drug Interactions - **Rifampin (strong CYP3A4/P-gp inducer)**: May significantly decrease linagliptin exposure; consider alternative agent. - **Other P-glycoprotein (P-gp) inducers (e.g., carbamazepine)**: May reduce linagliptin levels, monitor glycemic control. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline A1C and renal function. - **During Treatment**: Monitor A1C every 3-6 months. - **Clinical Signs**: Watch for signs of pancreatitis (severe abdominal pain), bullous pemphigoid (skin blisters/erosions), severe joint pain. ## Clinical Pearls - 💡 **Tip 1**: Linagliptin is unique among DPP-4 inhibitors as it requires no dose adjustment for renal or hepatic impairment. - 💡 **Tip 2**: Can be taken with or without food at any time of day. - 💡 **Tip 3**: Low risk of hypoglycemia when used as monotherapy or with metformin. Risk increases when combined with sulfonylureas or insulin. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.